How effective is methyldopa in primary hypertension?
Overall, the quality of evidence was compromised, secondary to the unclear nature of random sequence generation and allocation concealment procedures of almost all trials. Moreover, many of the trials did not report complete outcomes data (all cause mortality, cardiovascular mortality, non-cardiovascular mortality, serious adverse events, fatal and non-fatal myocardial infarction, and fatal and non-fatal stroke) for all randomised patients. Thus, the estimation of the true effect of methyldopa on outcomes, such as BP effects, is likely an overestimate.
Methyldopa is a centrally acting antihypertensive agent, which was commonly used in the 1970s and 1980s for BP control. It has largely been replaced by antihypertensive drug classes with fewer side effects, but it is still used in developing countries due to its low cost.